ABSTRACT We studied the intracellular transport of secretory and membrane proteins in the human hepatoma cell line HepG-2 infected with vesicular stomatitis virus. Cells were pulselabeled in the presence of [3SS]methionine and chased in the presence of the lysosomotropic agent primaquine. At a concentration of 0.3 mM primaquine effectively inhibited the secretion of albumin and, to a lesser extent, that of orosomucoid and transferrin. The drug also prevented the budding of virus particles at the cell surface. The intracellular transport to the Golgi complex of the membrane protein VSV-G was not affected by primaquine as it acquires resistance to endo-/~-N-acetylglucosaminidase H at the same rate as in control cells. Addition of primaquine at various times after the initiation of the chase period indicates that the effect of primaquine occurs just before secretion. In confirmation of the biochemical data, immunocytochemical localization of albumin in cells treated with NH4CI demonstrated that albumin accumulated in vesicles at the trans side of the Golgi complex. The effect of primaquine on secretion was also compared with its effect on receptor recycling. The dose-response characteristics of the effect of primaquine on receptor recycling are identical to those of the effects on protein secretion and virus budding. These results indicate that both processes involve the same transport mechanism, and/or that they occur via at least one identical intracellular compartment.
Secretory and plasma membrane proteins are transported from the rough endoplasmic reticulum (RER) ~ via the Golgi complex to the cell exterior. The transport rate between the RER and the Golgi complex differs for individual proteins and varies between 20 and 120 min. In rat and human hepatoma cells infected with vesicular stomatitis virus (VSV), albumin and the viral membrane protein VSV-G pass through the Golgi complex within 20 rain after synthesis, whereas transferrin remains in the RER for almost 2 h before acquisition of the complex sugar configuration (29) . After passage through the Golgi complex secretory and membrane (glyco)proteins rapidly (within a few minutes) reach the plasma membrane.
Abbreviations used in this paper: ASGP, asialoglycoprotein; ASOR, asialoorosomucoid; endo H, endo-a-N-acetylglucosaminidase; RER, rough endoplasmic reticulum; VSV, vesicular stomatitis virus.
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Another intracellular pathway in which proteins are specifically targetted along specific routes is that of receptor-mediated endocytosis of extracellular ligands. The occurrence of receptor recycling has been inferred from studies of a variety of receptor-ligand systems in many different cells, i.e., the receptor-mediated systems for delivery of low density lipoprorein, transferrin, lysosomal enzymes, and asialoglycoproteins (ASGPs) in hepatocytes. During receptor-mediated endocytosis, a ligand binds to a specific cell surface receptor, and the receptor-ligand complex is internalized via a coated pitcoated vesicle pathway. Many ligands dissociate from their receptor in a prelysosomal, acidic compartment and allow the receptors to recycle back to the cell surface (1, 27) . Neither the underlying mechanism nor the route for recycling of receptors back to the plasma membrane is known. From studies of the asialoglycoprotein receptor in a human hepa-tocyte-derived cell line, hepatoma HepG2, it is known that a single receptor molecule can recycle from the cell surface into a compartment of uncoupling receptor and ligand (CURL) within the cell and back to the cell surface within 8 rain (6, 9, 22) . Acidification within (some of) the endocytotic structures may play a role in ASGP-receptor recycling (25, 33) .
Both isolated endosomal and Golgi vesicles contain an H ÷ pump that results in acidification of these compartments (l 1, 35, 36) . Lysosomotropic agents such as the weak bases chloroquine, primaquine, and NI-LCI raise the pH of acidic intracellular compartments. Studies following the fate of receptors and labeled ligands demonstrate that these agents interrupt recycling of some receptors with their consequent accumulation in an endosomal compartment (3, 12, 25) . These observations suggest that the lysosomotropic amines inhibit the pathway by which the receptors return to the plasma membrane.
In the present study we have examined the effect of primaquine and NH4CI on the intracellular transport of secretory proteins and of the transmembrane glycoprotein VSV-G in human hepatoma HepG2 cells infected with vesicular stomatitis virus. In primaquine-treated cells the intracellular transport of secretory and membrane proteins is inhibited as compared with untreated cells. However, the degree of inhibition varies among the proteins examined. Both biochemical and immunoccytochemical findings demonstrate that the block is localized at or just distal to the trans side of the Golgi complex. In addition we have compared the effect of primaquine on protein secretion with its effect on the recycling of the ASGP-receptor.
MATERIALS AND METHODS

Cells and Viruses:
The human hepatoma cell line HepG2 (clone al6) was cultured in monolayer in Eagle's minimal essential medium containing 10% decomplemented fetal bovine serum (23) . The Indiana serotype of VSV was originally obtained from C. Pringle (Institute of Virology, Glasgow, U.K.). Maintenance of the cells and virus infection were detailed earlier (23, 29) .
Labeling of Cells:
Almost confluent HepG2 cells grown on 35-ram petri dishes were pulse-labeled with [3~S]methionine (20-30 #Ci/ml) (800-1,200 Ci/mmol; The Radiochemical Centre, Amersham U.K.), chased with unlabeled methionine, and lysed in 1% Triton X-100, 0.1 mM phenylmethylsulfonyl fluoride in phosphate-buffered saline (PBS). Primaquine (0.3 raM) was added after the radioactive labeling and was generally present throughout the entire chase period.
Immunoprecipitation and SDS PAGE:
Aliquotsofthe Triton X-100-soluble material were immunoprecipitated with either normal rabbit IgG (control) or affinity purified rabbit anti-rat ASGP-R, rabbit anti-human orosomucoid, rabbit anti-human albumin, rabbit anti-human transferrin (DAK-OPATTS, Denmark), monoclonal anti-VSV-G (clone c-l, a-7, kindly provided by Dr. M. Pasternak, Massachusetts Institute of Technology). Gel electrophoresis was performed in 10% polyacrylamide gels in the presence of SDS. Immunoprecipitations were performed as previously described (28) . After dec_ trophoresis the gels were fluorographed and the fluorograms were scanned with a mierodensitometer (E-C Apparatus Corp., St. Petersburg, FL) within the linear range of the film and the microdensitometer. Endo-B-N-acetylglucosaminidase H (undo H) digestion of immunoprecipitated proteins was performed as previously described (29) .
Binding of 1251-Asialoorosomucoid (12SI-ASOR) to Cell Surface:
The binding of ~2Sl-ASOR to HepG2 cells at 4"C has been described (23) ; specific binding is defined as the difference of binding of t2~I-ASOR in the absence and presence of 100-fold excess unlabeled ASOR. Binding was assayed in Eagle's minimal essential medium containing 10 mM HEPES (pH 7.3) during a 2-h period. scraped offofthe dish, and resuspended in 10% gelatin (37"C). After 2 min the suspension was centrifuged and the pellet was flattened at 0*C to provide a very thin layer of solidified gelatin containing the fixed cells. Cells were stored in 8% paraformaldehyde and 1 M sucrose at 4"C.
Cryosectioning, immunolabeling, staining, and embedding were carried out as detailed previously (9) . Double-immunogold labeling was performed as described (10) with two sizes of monodisperse colloidal gold particles, prepared according to Slot and Geaze (26) . Affinity purified antibodies were applied at a concentration of 0.05 mg/ml. Control sections were treated with affinity purified anti rat pancreatic amylase. Background labeling was negligible.
RESULTS
Effect of Primaquine on Secretion and Virus Production
To study the effect of primaquine on intracellular transport of secretory and membrane proteins HepG2 cells were infected with VSV and pulse-labeled in the presence of [355]-methionine. Fig. I . shows that both viral proteins and hepatoma specific secretory proteins appear in the tissue culture medium by 40 min of chase. Except for membrane glycoprotein G, viral proteins are incorporated into virus particles after short chases (radioactive VSV-M and VSV-N (NS) are clearly present). After longer chases various hepatoma products are secreted, albeit at different rates. In the presence of 0.3 mM primaquine the secretory process is markedly inhibited. Essentially no radioactive labeled albumin and VSV-G are present in the media after 3 h of chase. In addition, the process of virus budding is substantially reduced, as seen by the amount of VSV-L in the media. Quantitative immunoprecipitation of specific proteins present in the cells after various chase times is shown in Fig. 2 . The effect of primaquine on the secretion of individual proteins varies. Whereas albumin secretion is almost totally inhibited in the presence of 0.3 mM primaquine, the release of orosomucoid and transferrin is only delayed: half of the newly synthesized orosomucoid is normally secreted in <60 rain, whereas in the presence of primaquine > 120 rain are required for secretion of 50% of this protein. A similar delay is observed for the secretion of al-antitrypsin (not shown).
Primaquine Does Not Interfere with Protein Transport between the RER and the Golgi Complex
We have used the enzyme undo H as an analytical tool for transport of VSV-G from the RER to the Golgi complex. During this movement from the RER and through the Golgi complex, N-linked oligosaccharides undergo a number of modification reactions, including removal of three glucose and six mannose residues, and the subsequent addition of acetylglucosamine, galactose, and sialic acid. The enzymes involved in these reactions are presumably present at specific sites along the transport route through the RER and the Golgi complex (4, 31). The acquisition of resistance to undo H is thought to take place in the middle of the Golgi stack. Fig. 3 shows that in the presence or absence of primaquine the membrane protein VSV-G acquires resistance to undo H. This indicates that primaquine neither affects the initial processing of N-linked oligosaccharides nor alters the time required to reach the processing sites in the Golgi complex. Both in the presence and absence of primaquine more than 90% of VSV-G becomes endo H-resistant within 20 min of chase. 
Effect of Primaquine Removal on the Appearance of Secretory and Membrane Proteins at the Cell Exterior
The transport rate of glycoproteins between the RER and the Golgi complex was probed by the susceptibility to the enzyme endo H. These studies demonstrate that primaquine does not interfere with either the kinetics or route of the (glyco)proteins in this portion of their intracellular transport. To dissect further the localization of primaquine action we determined the effect of removal of the drug on the transport rate of newly synthesized proteins. VSV-infected HepG2 cells were pulse-labeled in the presence of [3SS]methionine and then chased in the presence or absence of primaquine for 2 h (Fig. 4) . In control cells (without primaquine) (Fig. 4, lanes 1-8) secretory proteins and virus particles began to appear in the medium within 30 min. Whereas some proteins reached a plateau shortly thereafter, other proteins initially appeared only after 60 or 90 min and did not reach a plateau even after 2 h of chase. In the presence of primaquine very little radio-STROUS active protein became apparent in the medium after 2 h of chase (Fig. 4, lane 9) . However, removal of primaquine from the cells was followed by a rapid secretion of the labeled proteins: after 5 or l0 min most proteins are easily identified in the medium. Quantification of the secretory products shows that the kinetics of secretion and virus budding are completely different in control and primaquine-treated cells (Fig. 5) . In the control situation individual proteins exhibit different rates of secretion, whereas after primaquine removal all secretory proteins leave the cells in synchrony. The effect of the removal of primaquine on protein secretion and on virus budding is again identical. Recovery of the cells after primaquine incubation for 2 h apparently is neither instantaneous nor complete, as it takes a considerable time for the proteins to be completely secreted. However, it is clear that incubation with primaquine does not interfere with the transport of membrane protein (i.e., VSV-G) or the secretory proteins through the intraceUular site at which these proteins are retarded differently on route to the plasma membrane. This site presumably lies before the Golgi complex (14) .
EX AL. Effect of Primaquine on Secretion and Receptor Recycling
FIGURE 3 endo H digestion of VSV-G. Labeling and sample preparation were as described in the legend to Fig. 1 
FIGURE 4 Effect of removal of primaquine on secretion. After VSV-infected cells were pulse-labeled for 10 min, the medium was replaced by 3-ml chase medium containing 50 #M unlabeled methionine and 0.3 mM primaquine. The cells were chased for 2 h at 37°C; then a 10-pl sample was taken for analysis by gel electrophoresis (lane 9). Thereafter the cells were put on ice and washed three times with 5 m[ PBS (pH 7.4) at 0°C for 5 min each to remove primaquine from the cells. 3 ml prewarmed chase medium (without primaquine) was then added, and 10-pl samples were taken at the times indicated in the figure for analysis by gel electrophoresis (lanes 10-18) . In control cells (no primaquine added) 10-pl samples were taken at the indicated times after the pulse labeling (lanes 1-8) . 
Where Does Primaquine Affect the Transport of Secretory Proteins?.
Thus far, the kinetic data localize the intracellular site of primaquine action to a position distal to both the RER and the cis-Golg~. To obtain a more precise picture of the primary effect VSV-infected HepG2 cells were pulse-labeled in the The proper exposure of the gel used in Fig. 4 (lanes 10-18) was scanned and the amounts of labeled protein were quantitated and plotted in the figure. The kinetics of secretion of albumin and VSV-G were identical in Fig. 4 ; O, albumin and VSV-G; @, VSV-L; "~, protein indicated with a star in Fig. 4 . A, control cells; B, cells chased in the presence of primaquine as described in the legend to Fig. 4 .
secretion almost totally during the remaining 100 or 110 min of chase. However, primaquine addition after 30 min failed to alter the appearance of most secretory proteins in the medium. Quantitation of the disappearance from the cells of albumin, orosomucoid, and transferrin after immunoprecipitation and gel electrophoresis (Fig. 7) allows the determination of the precise time after the initiation of the chase period at which the drug maximally interferes with the intracellular transport. The time at which 50% of the pulse-labeled albumin has passed the intracellular site of primaquine action is 24 min; orosomucoid requires 70 min and transferrin 115 min to arrive at this point. There is a remarkable similarity between these values and the times required for the secretion of these proteins. As the transport of secretory proteins in hepatoma cells is dependent mainly on the time required for transport between the RER and the Golgi complex (29) , it is clear that primaquine exerts its effect after the proteins have left the intracellular compartment where differences in transport rate arise.
Immunoelectron Microscopy
Immunocytochemistry of VSV-infected HepG2 cells makes it possible to characterize morphologically the site at which primaquine affects the intracellular transport. For these experiments we used NH4CI as the lysosomotropic amine, since primaquine inhibits protein synthesis substantially at the concentration required to inhibit secretion (0.3 raM). At a concentration of 10 mM NH4CI albumin synthesis is essentially unaffected, whereas its secretion is inhibited by 72%. By its immunogold labeling pattern in ultrathin cryosections we could localize the main concentration of albumin in control cells in the Golgi complex (Fig. 8A) . In ceils grown in the presence of NH4C1 larger vacuoles occurred, often at the trans side of the Golgi complex, in which albumin appeared to accumulate. As we pointed out in the introduction, lysosomotropic agents such as primaquine and NI-GC1 not only interfere with intracellular transport of secretory and membrane proteins, but they also dramatically affect the receptor-mediated endocytosis. Thus, we have compared the effect of lysosomotropic agents on the cellular distribution of albumin with that of the ASGP receptor. From sections co-labeled for STROUS albumin and the ASGP-receptor it is clear that both labels are present in the same diluted vesicles distal to the Golgi complex (Fig. 8 B) . Because of this localization these vesicles are probably trans-Gol# reticulum or secretory vesicles. Both albumin and ASGP-receptor labeling is scarce over the Golgi complex. These results indicate that after 2 h of NH,C1 treatment albumin accumulates in vesicles between the Golgi complex and the cell surface but not in the Golgi complex.
Comparison of the Drug Effects on Secretion and ASGP-Receptor Recycling
Studies of receptor-mediated endocytosis have shown that weak bases such as primaquine prevent the dissociation of FIGURE 6 Effect of primaquine on intracellular transport. VSVinfected cells were labeled as described in the legend to Fig. I and chased for 120 rain. At the indicated times primaquine was added to the chase medium (I ml). The cells were lysed in 0.5 ml lysis buffer and 10 ~.I was used for gel analysis (top). I0-,I aliquots of the media were also applied on a gel (bottom; lanes I-7). Lane ligand-receptor complexes within the endosomal compartment (CURL). This probably results from neutralization of the acid environment normally present in this compartment. In addition, in HepG2 cells in the absence of ligand primaquine also prevents the recycling back to the surface of the internalized ASGP receptor. However, this drug does not influence the rate at which the receptor enters the cell (25) . This behavior has enabled us to compare the effect of primaquine on the intracellular transport of secretory proteins (and virus budding) with its effect on the return of recycling receptors to the the plasma membrane. VSV-infected HepG-2 cells were incubated at 37"C in the presence of various concentrations of primaquine for 2 h in order to reach equilibrium. Thereafter the cells were chilled on ice and the number of cell surface ASGP-receptor binding sites was determined using 125I-ASOR. Since the number of receptors at the cell surface is determined by the concentration of primaquine, we can directly determine the dose-dependence of the return of receptor to the cell surface (Fig. 9B) . Fig. 9A shows the dose-dependent effect of primaquine on protein secretion and virus budding. Primaquine affects both ASGP-receptor recycling and protein secretion in exactly the same way, supporting the notion that both processes make use of a common mechanism.
DISCUSSION
The present results demonstrate that lysosomotropic agents such as NI-LCI and primaquine inhibit the intracellular transport of secretory and membrane proteins on route to the plasma membrane in a post-Golgi compartment. We have
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defined the site of primaquine action by three independent criteria: biochemically by the conversion of a "high mannose" to a "complex" sugar configuration of N-linked oligosaccharides as probed by sensitivity to endo H; kinetically by defining the actual intracellular transport rates; and morphologically by electron microscopic immunocytochemistry. The secretory transport route consists kinetically of at least two parts: from the RER to the Golgi complex and from the Golgi complex to the plasma membrane (2 l, 27). After synthesis in the RER (glyco)proteins are transported to the Golgi complex at different rates, presumably directed by interactions with components of the RER membranes. In some way these interactions induce differences in the transport rates for individual proteins, causing transport times to vary from 20 min for albumin to 2 h for transferrin (8, 14) . The second portion of the secretory pathway (Golgi complex-plasma membrane) may be either "regulated" or "constitutive" (30) . The regulated form of secretion occurs mainly in cells such as the pancreatic acinar cells, which after storage in granules secrete their proteins upon stimulation by calcium or cyclic AMP. The "unregulated" or "constitutive" pathway occurs in fibroblasts and macrophages and is insensitive to regulation by cyclic AMP or calcium. Hepatocytes and hepatoma cells secrete serum proteins as albumin, tranferrin, and a, antitrypsin in a constitutive manner. Pulse-chase experiments have shown that the transport from the Golgi complex to the plasma membrane is bulk-phase and that the time needed to reach the plasma membrane is relatively short (<5 min at 37"C) (14, 24, 29) . Primaquine primarily affects the second portion of the transport route. Our experiments demonstrate that addition of the drug at the end of the pulse labeling causes considerable delay in the secretion of albumin, orosomucoid, and transferrin. Moreover, the process of virus budding is blocked almost instantaneously. Moore et al. demonstrated that chloroquine at a concentration of 0.2 mM diverts ACTH from a regulated to a constitutive pathway in AtT-20 cells. Whether this lysosomotropic agent also affects the rate of ACTH secretion is not clear (16) . The mechanism of action of the lysosomotropic agents has been the subject of intensive investigation (reviewed in reference 7). This class of drugs inhibits lysosomal protein degradation at low concentrations (5, 34) and neutralizes the acidic environment in lysosomes and endosomes (15, 18, 19, 32) . Many of these actions may be a direct consequence of protonation within acidic intracellular compartments. Inhibition of transport by primaquine and NI-LCI suggests that the secretory proteins pass through such a compartment. Furthermore, the kinetics of this inhibitory effect provides evidence for the intracellular localization of such a compartment. However, the inhibition of secretory transport is not identical for all proteins. Recently Oda et al. described the effect of NH4CI on protein secretion (l 7). Consistent with our results, NI-LCI only partly inhibited a~-antitrypsin and total secretion in rat hepatocytes. It is possible that some transport to the plasma membrane continues to occur at the primaquine concentration used. This possibility is consistent with the slow and continued accumulation of labeled virus particles in the tissue culture medium in the presence of primaquine (Fig. l) . It is not now clear why the inhibition is different for individual proteins.
We have compared the effect of primaquine on protein secretion to its effect on ASGP receptor movement and localization. As we reported previously primaquine induces a inhibited in an identical manner suggests that bulk membrane transport to the cell surface is affected by primaquine. This idea is strengthened by the observation that virus budding is similarly inhibited by these agents, despite the fact that some of the nonintegral viral proteins are present and allow a modest degree of virus budding. Our results are consistent with a recent study of Robbins et al. on the effect of a single mutation in Chinese hamster ovary cells with respect to Golgi complex and endosomal function. They report a striking similarity between the alterations in both endocytotic and Golgi-associated steps of the maturation of viral proteins in a mutant cell line that exhibits a decreased ATP-dependent endosome acidification (20) .
